Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + mFOLFIRINOX in Borderline Resectable Pancreatic Cancer
NCT03970252Phase 1Completed
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Jul 2019
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nivolumab in pancreatic adenocarcinoma (PDAC), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoints: Clinically relevant pancreatic fistula in the post-operative period up to 3 years and Pathologic Complete Response up to 3 years. Started Jul 2019; status: completed.
02
Drugs
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03970252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03970252.